Biotech

On Sat. Sept 25th at 5pm EST broadcast on FOX Business News - BTV-Business Television visits up-and-coming innovative investment opportunities.

Discover Companies to Invest In - Watch their TV feature!

Osisko Metals (TSXV: OM) (OTCQX:OMZNF) - As electric transportation rises in popularity, the zinc demand increases and Osisko is poised to take advantage with their advanced zinc projects.

Fobi AI (TSXV: FOBI) (OTCQB: FOBIF) - BTV showcases their innovative AI device that provides real time data connectivity to retailers for increased profitability.

Rritual Superfoods(CSE: RSF) - BTV visits a company aiming to be the premium brand in the superfood space with its mushrooms and herbal adaptogen products.

Desert Mountain Energy (TSXV: DME) (OTCQX: DMEHF) - From helping launch rockets to driving antibiotics deep into the lungs of COVID patients, helium has many uses and Desert Mountain is gearing up to meet this growing demand.

Giga Metals (TSXV: GIGA) (OTCQB: HNCKF) - With nickel as one of the key minerals required in EV batteries, Giga is on point with one of the world's largest undeveloped nickel-cobalt sulphide deposits.

Lexaria Bioscience (CSE: LXX) (NASDAQ: LEXX) - A leading bioscience company whose patented technology, DehydraTECH, provides a faster and more effective drug delivery method.

About BTV:

On air for more than 20 years, BTV - Business Television, a half-hour investment TV show, features analysts and emerging companies on location. With Hosts, Taylor Thoen and Jessica Katrichak, BTV provides viewers with investment opportunities.

TV BROADCAST NETWORKS and TIMES:
FOX Business News US: Sat. Sept 25th 5pm EST.

Suggest a Company to Feature!
Contact: (604) 664-7401 x3 info@b-tv.com
To receive news, click here to subscribe

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97377

News Provided by Newsfile via QuoteMedia

European Commission Grants Expanded Marketing Authorization for Gilead's Biktarvy® for the Treatment of HIV in Pediatric Populations

EC Authorizes a Low-Dose Tablet for HIV Treatment in Virologically Suppressed Children at Least Two Years of Age and Weighing at Least 14 kg, Helping to Address a Critical Unmet Need –

– Biktarvy Provides an Effective Therapy Choice for a Diverse Range of People Living with HIV, including Children with Limited Treatment Options –

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Envisagenics Announces Research Collaboration with Bristol Myers Squibb

Collaboration will leverage Envisagenics' SpliceCore® AI platform for accelerated discovery and development of oncology therapeutic candidates

Envisagenics an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol Myers Squibb (NYSE: BMY). The multi-year collaboration will leverage Envisagenics' SpliceCore® AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb's vast oncology pipeline. Envisagenics will receive an upfront payment and milestone payments based on development, regulatory, and commercial achievements.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Komo Reports Fiscal Year 2022 Financial Results

Komo Reports Fiscal Year 2022 Financial Results

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) ("Komo"), a premium plant-based food company, today reports financial results for the year ended July 31, 2022.

"We began our fiscal year as a new brand with a mission to make plant-based meals a staple on every dinner table by sharing our love for feel-good food that connects the people to the planet. Thanks to the strength of our team and the love of Komo products, we were successful in achieving sales growth of 935 percent over last year," says Komo founder and CEO William White. "The consistently strong retail sales of our products have allowed us to demonstrate to large retail chains that our products sell well and have repeat customers. We recently completed a national listing with Loblaws and we are in discussions with several other large national chains. As a result, we are anticipating continued significant revenue increases in 2023."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Grant of Stock Options

The Gummy Project Announces Grant of Stock Options

The Gummy Project Inc. (CSE: GUMY) (FSE: 0OS0) (OTCQB: GUMYD) ("GUMY" or the "Company") announces that it has issued a total of 2,300,000 stock options pursuant to its incentive stock option plan ("Plan") to consultants which vest on the grant date. Each option entitles the holder to subscribe for one common share of the Company for $0.06 for a period of 5 years, subject to the terms of the Plan. Over the past quarter, 1,664,800 options have lapsed or been cancelled.

About The Gummy Project

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m. ET on Monday Dec. 5, 2022. David M. Reese M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's R&D team, will discuss the Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule.

The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer

Fourth Interim Analysis Shows Continued Clinically Meaningful Differentiation Across All Efficacy Measures, Including PFS, in Both Domvanalimab-Containing Arms Compared to the Anti-PD-1 Zimberelimab Monotherapy Arm in First-Line NSCLC Patients –

Data will be Presented on December 20, 2022 at the American Society of Clinical Oncology (ASCO) Monthly Plenary Series

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×